DailyTimeCapsule brief
December 16, 2000
On December 16, 2000, a pivotal moment erupted in the pharmaceutical industry as a division of a major drug giant entered a guilty plea related to illegal marketing practices. This event underscored growing regulatory scrutiny over pharmaceutical marketing methods and highlighted the broader concerns about corporate compliance in the late 1990s and early 2000s, a period marked by increasing health care costs and public skepticism towards the pharmaceutical sector. Concurrently, the oil and gas industry began to show signs of recovery, with natural gas prices reaching record levels, signaling a potential turnaround after years of volatility. As the nation was entering a new millennium, economic forecasts were cautiously optimistic, reflecting the complexities of the market and consumer confidence in various sectors of the economy.
Key developments
-
In a significant legal outcome, LifeScan, a subsidiary of Johnson & Johnson, pleaded guilty to criminal charges regarding the sale of defective blood glucose monitoring devices intended for diabetic patients. The company was found to have submitted false information to federal regulators about the issues with these devices, potentially compromising patient health and safety. As a consequence, LifeScan agreed to pay a hefty settlement of $60 million to address the allegations and the resulting damage to public trust.
-
Oil Patch Is Coming Back to Life As Natural Gas Prices Set Record
